Revvity, Inc. (RVTY) has a MoatMap StockRank of 69/100 based on Quality (51/100), Value (35/100), and Momentum (67/100) factor scores. The current signal is BUY. Revvity provides critical life sciences tools and diagnostic reagents that serve as essential inputs for CDMOs and biotech innovators, offering a high-margin, recurring-revenue play on drug development without direct manufacturing risk.
Revvity, Inc. is a global life sciences and diagnostics company focused on improving human health through innovative technologies and services. The company provides a broad portfolio of instruments, reagents, software, and services for genomics, proteomics, cellular analysis, and diagnostics. Revvity holds a strong position in research and clinical markets due to its comprehensive solutions, strong R&D capabilities, and global reach, serving academic, pharmaceutical, and diagnostic customers.
| Price | $104.13 |
| Market Cap | $11.3B |
| P/E (TTM) | 49.23 |
| P/E (Forward) | 17.59 |
| Price/Book | 1.59 |
| Return on Equity | 3.2% |
| Return on Invested Capital | 3.3% |
| Debt/Equity | 46.64 |
| Gross Margin | 54.3% |
| Operating Margin | 12.4% |
| Revenue Growth | 7.0% |
| Dividend Yield | 0.3% |
| Free Cash Flow | $509M |
Revvity, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).